van Melle JPDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Wolff DDepartment of Pediatric Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Hörer JTechnical University, German Heart Center Munich, Munich, Germany.
Belli EDepartment of Congenital Heart Disease, Centre Chirurgical Marie Lannelongue, Paris, France.
Meyns BDepartment of Cardiac Surgery, Catholic University Leuven, Leuven, Belgium.
Padalino MPediatric and Congenital Cardiovascular Surgery Unit, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padua, Italy.
Lindberg HDepartment of Thoracic and Cardiovascular Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
Jacobs JPJohns Hopkins All Children's Heart Institute, All Children's Hospital and Florida Hospital for Children, Saint Petersburg, Tampa, and Orlando, Florida, USA Johns Hopkins University, Baltimore, Maryland, USA.
Mattila IPHospital for Children and Adolescents, University of Helsinki, Helsinki, Finland.
Berggren HChildren's Heart Centre, The Queen Silvia Children's Hospital, Gothenburg, Sweden.
Berger RMDepartment of Pediatric Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Prêtre RClinic for Cardiovascular Surgery, University Hospital Zurich, Zurich, Switzerland.
Hazekamp MGLeiden University Medical Center, Leiden, The Netherlands Academic Medical Center, Amsterdam, The Netherlands.
Helvind MDepartment of Cardio-Thoracic Surgery, University Hospital of Copenhagen, Copenhagen, Denmark.
Nosál MNational Institute of Cardiovascular Disease, Children's Heart Centre Slovak Republic, Bratislava, Slovakia.
Tlaskal TDepartment of Pediatric Cardiac Surgery, Children's Heart Center, Motol University Hospital, Prague, Czech Republic.
Rubay JDivision of Cardiac Surgery, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
English
OBJECTIVE The objective of this European multicenter study was to report surgical outcomes of Fontan takedown, Fontan conversion and heart transplantation (HTX) for failing Fontan patients in terms of all-cause mortality and (re-)HTX.
METHODS A retrospective international study was conducted by the European Congenital Heart Surgeons Association among 22 member centres. Outcome of surgery to address failing Fontan was collected in 225 patients among which were patients with Fontan takedown (n=38; 17%), Fontan conversion (n=137; 61%) or HTX (n=50; 22%).
RESULTS The most prevalent indication for failing Fontan surgery was arrhythmia (43.6%), but indications differed across the surgical groups (p<0.001). Fontan takedown was mostly performed in the early postoperative phase after Fontan completion, while Fontan conversion and HTX were mainly treatment options for late failure. Early (30 days) mortality was high for Fontan takedown (ie, 26%). Median follow-up was 5.9 years (range 0-23.7 years). The combined end point mortality/HTX was reached in 44.7% of the Fontan takedown patients, in 26.3% of the Fontan conversion patients and in 34.0% of the HTX patients, respectively (log rank p=0.08). Survival analysis showed no difference between Fontan conversion and HTX (p=0.13), but their ventricular function differed significantly. In patients who underwent Fontan conversion or HTX ventricular systolic dysfunction appeared to be the strongest predictor of mortality or (re-)HTX. Patients with valveless atriopulmonary connection (APC) take more advantage of Fontan conversion than patients with a valve-containing APC (p=0.04).
CONCLUSIONS Takedown surgery for failing Fontan is mostly performed in the early postoperative phase, with a high risk of mortality. There is no difference in survival after Fontan conversion or HTX.